Abstract

The clinical approach to older patients with myeloma has to be modified to take into account co-morbidities and the likelihood of higher treatment-related toxicity. Individualization of management and adequate supportive therapy are important to obtain the best response while minimizing adverse effects. Corticosteroids, novel agents, conventional cytotoxic agents, and high-dose chemotherapy with autotransplantation – modalities used in younger patients – are also used in older patients, although...